Почетна › Рак јетре (хепатоцелуларни карцином) › Minesota
Kliničke studije za Рак јетре (хепатоцелуларни карцином) u državi Minesota
21 studija za Рак јетре (хепатоцелуларни карцином) traži učesnike na lokacijama u državi Minesota.
Gradovi u državi Minesota
Zvanični tekst studije (na engleskom)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Minneapolis VA Medical Center, Minneapolis
Тражи се учесникЗдраве особе су добродошле
Узраст од 45 до 75 · Оба пола · Ажурирано 6. 11. 2026. · NCT06995898A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Rochester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06600321A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06330064A Phase 1 Study of the Safety and Tolerability of CTX-10726
- Mayo Clinic Rochester, Rochester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07419841A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 121, Saint Paul
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT05914116Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Rochester
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06921785Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Allina Health Cancer Institute - Mercy Hospital, Coon Rapids
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
- Allina Health Cancer Institute - United Hospital, Saint Paul
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07227012FOG-001 in Locally Advanced or Metastatic Solid Tumors
- M Health Fairview University of Minnesota Medical Center, Minneapolis
- Mayo Clinic, Rochester
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 7. 10. 2026. · NCT05919264Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
- Mayo Clinic in Rochester, Rochester
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT03942328Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #68, Rochester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT05176483Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, Rochester
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT06726161National Liver Cancer Screening Trial
- Hennepin Healthcare, Minneapolis
- University of Minnesota, Minneapolis
Тражи се учесникФаза 4
Узраст од 18 до 85 · Оба пола · Ажурирано 25. 9. 2026. · NCT06084234Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- University of Minnesota/Masonic Cancer Center, Minneapolis
Тражи се учесникФаза 1/2
12 Months – 30 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT04851119Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- и још 5
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT07166406Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Mayo Clinic in Rochester, Rochester
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 8. 2026. · NCT05168163A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- St. Luke's Hospital, Duluth
Тражи се учесникФаза 2
Узраст 8 и старији · Оба пола · Ажурирано 27. 7. 2026. · NCT05503797DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
- Mayo Clinic, Rochester
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 21. 7. 2026. · NCT07717437Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
- Mayo Clinic in Rochester, Rochester
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 12. 3. 2026. · NCT06349642SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774The Dragon PLC Trial (DRAGON-PLC)
- Mayo Clinic, Rochester
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 15. 5. 2025. · NCT06914648A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Mayo Clinic in Minnesota, Rochester
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 25. 11. 2024. · NCT05824975Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.